# Rapport Therapeutics, Inc. (RAPP) EPS: -$2.86 in 2025

URL: https://funkfolio.com/stock/RAPP/eps

> Rapport Therapeutics, Inc. (RAPP) earnings per share (EPS) was -$2.86 in fiscal 2025. 3 fiscal years of history in a chart and a table.

---

## Rapport Therapeutics, Inc. (RAPP) earnings per share (EPS)

**Earnings per share · fiscal 2025:** -$2.86 year ended Dec 31, 2025

Rapport Therapeutics, Inc. (RAPP) reported diluted earnings per share of -$2.86 in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$3.78. Figures as of 17 Nov 2026, 21:40 UTC, from Yahoo Finance.

### Key facts

- **Earnings per share, fiscal 2025:** -$2.86
- **Highest on record:** -$2.86 fiscal 2025
- **Lowest on record:** -$23.10 fiscal 2023
- **Fiscal years on record:** 3 2023–2025

Figures as of 17 Nov 2026, 21:40 UTC. Statements from Yahoo Finance. Amounts are in USD. Figures, not advice.

### Rapport Therapeutics, Inc. earnings per share (EPS), in more detail

Across the 3 fiscal years on record (2023–2025), the highest was -$2.86 in fiscal 2025 and the lowest -$23.10 in fiscal 2023.

### Earnings per share by fiscal year

### Rapport Therapeutics, Inc. earnings per share (EPS), year by year

Rapport Therapeutics, Inc. (RAPP) earnings per share (EPS) by fiscal year

| Fiscal year | Earnings per share | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | -$2.86 | — | Dec 31, 2025 |
| 2024 | -$3.78 | — | Dec 31, 2024 |
| 2023 | -$23.10 | — | Dec 31, 2023 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.

### How to read it

It shows how much profit stands behind each share, so it rises when profit grows or when buybacks shrink the share count.

### Rapport Therapeutics, Inc., figure by figure

- [Rapport Therapeutics, Inc. market cap](https://funkfolio.com/stock/RAPP/market-cap)
- [Rapport Therapeutics, Inc. revenue](https://funkfolio.com/stock/RAPP/revenue)
- [Rapport Therapeutics, Inc. earnings](https://funkfolio.com/stock/RAPP/earnings)
- [Rapport Therapeutics, Inc. P/E ratio](https://funkfolio.com/stock/RAPP/pe-ratio)
- [Rapport Therapeutics, Inc. P/S ratio](https://funkfolio.com/stock/RAPP/ps-ratio)
- [Rapport Therapeutics, Inc. P/B ratio](https://funkfolio.com/stock/RAPP/pb-ratio)
- [Rapport Therapeutics, Inc. free cash flow](https://funkfolio.com/stock/RAPP/free-cash-flow)
- [Rapport Therapeutics, Inc. operating margin](https://funkfolio.com/stock/RAPP/operating-margin)
- [Rapport Therapeutics, Inc. dividend](https://funkfolio.com/stock/RAPP/dividend)
- [Rapport Therapeutics, Inc. shares outstanding](https://funkfolio.com/stock/RAPP/shares-outstanding)
- [Rapport Therapeutics, Inc. total debt](https://funkfolio.com/stock/RAPP/total-debt)
- [Rapport Therapeutics, Inc. cash on hand](https://funkfolio.com/stock/RAPP/cash)
- [Rapport Therapeutics, Inc. total assets](https://funkfolio.com/stock/RAPP/total-assets)
- [Rapport Therapeutics, Inc. return on equity (ROE)](https://funkfolio.com/stock/RAPP/roe)
- [Rapport Therapeutics, Inc. return on invested capital (ROIC)](https://funkfolio.com/stock/RAPP/roic)

[Rapport Therapeutics, Inc. (RAPP) overview: price, valuation and scorecard](https://funkfolio.com/stock/RAPP)

### Rapport Therapeutics, Inc. earnings per share (EPS): questions and answers

**What is Rapport Therapeutics, Inc.'s diluted earnings per share?**

Rapport Therapeutics, Inc. (RAPP) reported diluted earnings per share of -$2.86 in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$3.78.

**What are the highest and lowest diluted earnings per share figures on record for Rapport Therapeutics, Inc.?**

Across the 3 fiscal years on record (2023–2025), the highest was -$2.86 in fiscal 2025 and the lowest -$23.10 in fiscal 2023.

**How is Rapport Therapeutics, Inc.'s diluted earnings per share calculated?**

Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.

Fiscal years are named for the calendar year they end in.

### Learn: earnings per share (EPS)

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Revenue vs earnings vs free cash flow: what each tells you](https://funkfolio.com/learn/stocks/revenue-earnings-free-cash-flow)

  Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- [P/E ratio explained: what a high or low figure means](https://funkfolio.com/learn/stocks/pe-ratio)

  The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.

### Cite this page

Funkfolio, “Rapport Therapeutics, Inc. (RAPP) earnings per share (EPS)”, data as of 17 November 2026. https://funkfolio.com/stock/RAPP/eps

Underlying data: Yahoo Finance.
